← Back

Zhejiang Benli Technology Co. Ltd.

Zhejiang Benli Technology Co., Ltd. is a Chinese company engaged in the research, development, production, and sales of pharmaceutical, pesticide, and new material intermediates. Its products include 2,4-Dichloro-5-fluorobenzoyl chloride, 2-(2,4-Dichloro-5-fluorobenzoyl)-3-cyclopropylamine ethyl acrylate, 1-Ethyl-7-(1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid hydrochloride, 2,4-Dichlorofluorobenzene, Methyl 3-methoxyacrylate, Ethyl N,N-dimethylaminoacrylate, 2,6-Dichlorofluorobenzene, and 3-(2-Ethylene Glycol Methyl Ether)-2-Methyl-4-Methanesulfonyl benzoic acid. The company was founded in 2011 and is based in Linhai, China.

Country
Price · split & dividend adjusted
News & notes moving 301065.CS
301065.CS

Benli Technology Approved to Produce Norfloxacin API

Zhejiang Benli Technology Co., Ltd. announced that it has received approval from the Zhejiang Medical Products Administration to adjust the production scope of its norfloxacin active pharmaceutical ingredient from 'registration application use only' to formal production. The production site, production line, and workshop remain unchanged, and a new drug GMP compliance inspection number has been added. The company stated that this change will not have a significant impact on its performance in the short term, but future sales are subject to uncertainty due to policy and market environment factors.
Jiemian·10dRead more →
301065.CS

Benli Technology Releases 2026 Interim Report with Net Profit of 44.7691 Million Yuan

Benli Technology released its 2026 interim report. The company's total operating revenue was 370 million yuan, and net profit attributable to the parent company was 44.7691 million yuan. Net cash inflow from operating activities was 27.0572 million yuan, a decrease of 48.183 million yuan compared with the same period last year, down 64.04 percent year on year. The company's latest asset-liability ratio was 15.92 percent, up 1.10 percentage points from the previous quarter. Gross margin was 26.11 percent, return on equity was 3.21 percent, and diluted earnings per share was 0.43 yuan.
Jiemian·25dRead more →
301065.CS2

Benli Technology's interim revenue rises 8.15%, operating cash flow falls 64%

Benli Technology released its 2026 interim report, with operating revenue of 370 million yuan, up 8.15% year on year, and net profit attributable to the parent of 44.77 million yuan, up 0.24% year on year. However, net cash flow from operating activities was 27.06 million yuan, a sharp decline of 64.04% from 75.24 million yuan in the same period last year. Revenue from the 801 product was 78.60 million yuan, up 57.23% year on year, with gross margin up 10.63 percentage points to 42.91%, making it the main growth driver. Revenue from the 1201 product was 56.68 million yuan, up 39.33% year on year. Revenue from the 1701 product was 66.03 million yuan, up 16.08% year on year. Meanwhile, the 1501 product, which had the largest revenue share, posted revenue of 102 million yuan, down 26.40% year on year, offsetting growth in other products. The decline in operating cash flow was mainly due to a reduction in cash received from sales of goods, with the closing cash balance down by about 171 million yuan from the beginning of the period.
蓝鲸财经·26dRead more →
301065.CS

Benli Technology's first-half 2026 net profit reaches 44.7691 million yuan, up 0.24% year on year

Benli Technology disclosed its 2026 semi-annual report. In the first half, it achieved total operating revenue of 370 million yuan, up 8.15% year on year. Net profit attributable to the parent company was 44.7691 million yuan, up 0.24% year on year. Net profit after deducting non-recurring items was 42.1088 million yuan, down 0.32% year on year. Net cash flow from operating activities was 27.0572 million yuan, down 64.04% year on year. Basic earnings per share were 0.43 yuan, and the weighted average return on equity was 3.20%.
中国证券报·26dRead more →
301065.CS

Benli Technology's Norfloxacin Workshops and Production Lines Pass GMP Compliance Inspection

Benli Technology announced that its A4, A5, and A2 workshops and production lines for the active pharmaceutical ingredient norfloxacin have passed the GMP compliance inspection by the Zhejiang Medical Products Administration. This inspection confirms that the relevant facilities meet the requirements of Good Manufacturing Practice for pharmaceutical products, laying the foundation for the commercial production and supply of norfloxacin. In the first quarter of 2026, Benli Technology achieved revenue of 162 million yuan and net profit attributable to the parent company of 10.59 million yuan.
财中社·52dRead more →